共 52 条
Serum anandamide and lipids associated with linoleic acid can distinguish interstitial cystitis/bladder pain syndrome from overactive bladder: An exploratory study
被引:1
作者:
Torimoto, Kazumasa
[1
,4
]
Ueda, Tomohiro
[2
]
Gotoh, Daisuke
[1
]
Kano, Kuniyuki
[3
]
Miyake, Makito
[1
]
Nakai, Yasushi
[1
]
Hori, Shunta
[1
]
Morizawa, Yosuke
[1
]
Onishi, Kenta
[1
]
Shimizu, Takuto
[1
]
Tomizawa, Mitsuru
[1
]
Aoki, Junken
[3
]
Fujimoto, Kiyohide
[1
]
机构:
[1] Nara Med Univ, Dept Urol, Nara, Japan
[2] Ueda Urol Clin, Kyoto, Japan
[3] Univ Tokyo, Grad Sch Pharmaceut Sci, Dept Hlth Chem, Tokyo, Japan
[4] 840 Shijo cho, Kashihara, Nara 6348522, Japan
关键词:
anandamide;
bladder pain syndrome;
endocannabinoid;
interstitial cystitis;
linoleic acid;
CANNABINOID RECEPTOR 2;
AMIDE HYDROLASE FAAH;
ENDOCANNABINOID SYSTEM;
INHIBITION;
EXPRESSION;
MOUSE;
D O I:
10.1111/luts.12501
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
Objectives: Diagnosing interstitial cystitis/bladder pain syndrome presents a major challenge because it relies on subjective symptoms and empirical cystoscopic findings. A practical biomarker should discriminate diseases that cause increased urinary frequency, particularly overactive bladder. Therefore, we aimed to identify blood biomarkers that can discriminate between interstitial cystitis/bladder pain syndrome and overactive bladder.Methods: We enrolled patients with Hunner-type interstitial cystitis (n = 20), bladder pain syndrome (n = 20), and overactive bladder (n = 20) and without lower urinary tract symptoms (controls, n = 15) at Ueda Clinic and Nara Medical University Hospital from February 2020 to August 2021. The degree of interstitial cystitis/bladder pain syndrome symptoms was evaluated using the interstitial cystitis symptom and problem indices. Metabolomics analysis was performed on 323 serum metabolites using liquid chromatography time-of-flight mass spectrometry.Results: In the Hunner-type interstitial cystitis or bladder pain syndrome group, we observed smaller relative areas, including anandamide, acylcarnitine (18:2), linoleoyl ethanolamide, and arachidonic acid, compared to those in the overactive bladder or control group. Notably, the differences in the relative areas of anandamide were statistically significant (median: 3.950e-005 and 4.150e-005 vs. 8.300e-005 and 9.800e-005), with an area under the curve of 0.9321, demonstrating its ability to discriminate interstitial cystitis/bladder pain syndrome.Conclusions: serum anandamide may be a feasible diagnostic biomarker for interstitial cystitis/bladder pain syndrome. Reduced serum anandamide levels may be associated with pain and inflammation initiation, reflecting the pathology of interstitial cystitis/bladder pain syndrome. Furthermore, our findings suggest that abnormal linoleic acid metabolism may be involved in the pathogenesis of interstitial cystitis/bladder pain syndrome.
引用
收藏
页码:238 / 246
页数:9
相关论文